Marshall Wace, LLP Acrivon Therapeutics, Inc. Transaction History

Marshall Wace, LLP

  • $74.4 Billion
  • Q1 2025

A detailed history of Marshall Wace, LLP transactions in Acrivon Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 450,391 shares of ACRV stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
450,391
Previous 597,794 24.66%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
SELL
N/A
-147,403 Reduced 24.66%
450,391 $0
Q4 2024

Feb 13, 2025
SELL
N/A
-212,065 Reduced 26.19%
597,794 $0
Q3 2024

Nov 14, 2024
SELL
N/A
-139,007 Reduced 14.65%
809,859 $0
Q2 2024

Aug 14, 2024
BUY
N/A
351,397 Added 58.81%
948,866 $0
Q1 2023

May 15, 2023
SELL
N/A
-625,783 Reduced 51.16%
597,469 $0
Q4 2022

Feb 14, 2023
BUY
N/A
1,223,252 New
1,223,252 $0

Others Institutions Holding ACRV

# of Institutions
55
Shares Held
22.6M
Call Options Held
0
Put Options Held
0
View Full List

About Acrivon Therapeutics, Inc.

ACRV Quotes by TradingView
  • Ticker ACRV
More about ACRV
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email